To investigate the functional contribution of PD-L1 to the beneficial therapeutic effects of OM-MOG in vivo, we administered a neutralizing anti-PD-L1 antibody to EAE mice receiving therapeutic OM-MOG injections. The gene discussed is CD274; the disease is ocular melanoma.